IL-13Rα2 Is a Biomarker of Diagnosis and Therapeutic Response in Human Pancreatic Cancer.
AP-1 pathway
IL-13Rα2
cancer invasion
metastasis
pancreatic cancer
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
23 Jun 2021
23 Jun 2021
Historique:
received:
06
04
2021
revised:
08
06
2021
accepted:
18
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
IL-13Rα2 is a high-affinity binding protein for its ligand IL-13 and a cancer-testis antigen as it is expressed in the testis. IL-13Rα2 is highly expressed in various cancers, including pancreatic cancer, and consists of three domains: extracellular, transmembrane, and cytoplasmic. The extracellular domain binds to the ligand to form a biologically active complex, which initiates signaling through AP-1 and other pathways. IL-13Rα2 is also expressed in diseased cells such as fibroblasts that are involved in various inflammatory diseases, including cancer. We have reported that IL-13Rα2 is a prognostic biomarker for malignant glioma, adrenocortical cancer, and pancreatic cancer. In pancreatic cancer, a small sample of tissue could be examined for the expression of IL-13Rα2 by using the endoscopic ultrasound-fine needle aspiration technique (EUS-FNA). In addition, a peptide-based targeted approach using Pep-1L peptide could be used to study the biodistribution and whole-body cancer imaging for the screening of pancreatic cancer in suspected subjects.
Identifiants
pubmed: 34201539
pii: diagnostics11071140
doi: 10.3390/diagnostics11071140
pmc: PMC8303581
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Sci Rep. 2019 Feb 4;9(1):1281
pubmed: 30718742
Cancers (Basel). 2020 May 20;12(5):
pubmed: 32443847
J Exp Med. 2003 Mar 17;197(6):675-9
pubmed: 12642599
EPMA J. 2019 Aug 29;10(4):395-414
pubmed: 31832114
Cancers (Basel). 2019 Sep 26;11(10):
pubmed: 31561550
Biosens Bioelectron. 2018 Oct 15;117:766-772
pubmed: 30029198
Mol Cancer Ther. 2004 Feb;3(2):137-47
pubmed: 14985454
J Clin Endocrinol Metab. 2009 Aug;94(8):2952-7
pubmed: 19491224
Oncotarget. 2016 Aug 2;7(31):49281-49288
pubmed: 27351230
Cancer Res. 2008 Nov 15;68(22):9311-7
pubmed: 19010904
Nat Commun. 2017 Dec 4;8(1):1913
pubmed: 29203859
J Mol Biol. 2017 Jan 20;429(2):208-219
pubmed: 27956146
J Transl Med. 2011 Apr 08;9:37
pubmed: 21477288
Cancer Res. 2009 Nov 15;69(22):8678-85
pubmed: 19887609
J Biol Chem. 1997 Aug 8;272(32):20251-8
pubmed: 9242704
Nature. 1993 Mar 18;362(6417):248-50
pubmed: 8096327
Cytokine. 2015 Sep;75(1):68-78
pubmed: 26070934
Dig Endosc. 2017 May;29(4):417-430
pubmed: 28140485
Breast Cancer Res. 2015 Jul 25;17:98
pubmed: 26208975
J Transl Med. 2018 Dec 20;16(1):369
pubmed: 30572904
Nat Immunol. 2000 Dec;1(6):515-20
pubmed: 11101874
Cancer. 2012 Nov 15;118(22):5698-708
pubmed: 22570059
Cytokine. 2015 Sep;75(1):79-88
pubmed: 26088753
Cytokine. 2015 Sep;75(1):38-50
pubmed: 26187331
Clin Cancer Res. 2010 Jan 15;16(2):577-86
pubmed: 20068108
Oncotarget. 2017 Mar 24;8(31):50997-51007
pubmed: 28881623
Cancer Res. 2012 Jun 1;72(11):2780-90
pubmed: 22505647
Vitam Horm. 2006;74:479-504
pubmed: 17027527
Tumour Biol. 2016 Nov;37(11):14701-14709
pubmed: 27623944
Cell. 2008 Jan 25;132(2):259-72
pubmed: 18243101
Cancer. 2006 Sep 15;107(6):1407-18
pubmed: 16902988
Int J Cancer. 2012 Jul 15;131(2):344-56
pubmed: 21858811
J Neurooncol. 2018 Feb;136(3):463-474
pubmed: 29168083
Int Immunopharmacol. 2021 Jan;90:107155
pubmed: 33243603
Br J Cancer. 2018 Oct;119(8):940-949
pubmed: 30318506
Immunotherapy. 2009 May;1(3):321-7
pubmed: 20635949